US Patent

US9345772 — Liquid levothyroxine formulations

Formulation · Assigned to Individual · Expires 2035-02-27 · 9y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects liquid formulations of levothyroxine that contain specific concentrations of levothyroxine, glycerol, water, and EDTA.

USPTO Abstract

Embodiments of the present invention provide levothyroxine solutions that consist of from about 0.001% w/v to about 0.01% w/v of a levothyroxine; at least 70% w/w of a glycerol; less than 30% w/w of a water; and from about 0.01% w/w to about 1.5% w/w of an ethylenediaminetetraacetic acid (EDTA). Such levothyroxine solutions are characterized by exhibiting levothyroxine storage stability.

Drugs covered by this patent

Patent Metadata

Patent number
US9345772
Jurisdiction
US
Classification
Formulation
Expires
2035-02-27
Drug substance claim
No
Drug product claim
Yes
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.